The Marius Team consists of unique blend of long-time Pharma industry veterans from both the Branded and Generic worlds with deep experience in Drug Development, Clinical Trials, Manufacturing, Commercialization, and Business Strategy.
Om Dhingra, Ph.D
CHIEF EXECUTIVE OFFICER Dr. Dhingra has more than 20 years experience in pharmaceutical industry leading discovery & development of drugs for Metabolic, Viral, Oncology and Diseases of Aging. He founded Differential Drug Development Associates (DDDA) in 2008, and developed a drug delivery technology for enhancing solubility, metabolic stability, and absorption of lipophilic compounds. In 2009, he founded SOV Therapeutics, Inc. focusing on utilizing the delivery technology for the development of a new standard of care in testosterone replacement therapy for adults. Prior to founding DDDA and SOV Therapeutics, Inc., he worked for GSK and heritage companies for 17 years starting in 1991 as Head of Structural Chemistry and progressed to Vice President and Head of Preclinical Drug Discovery and Development for the Center Of Excellence in Metabolic Diseases. At GSK, he was responsible for leading several key initiatives to improve efficiency and effectiveness of preclinical development, first time in human and clinical proof of concept. During his tenure at GSK, he was responsible for successful preclinical development of two anti‐virals, one diseases of aging, and one oncology drug currently marketed by GSK.Combined sales of these drugs in 2012 were >$1B.
CHIEF FINANCIAL OFFICER Shalin Shah serves as Chief Financial Officer of Marius Pharmaceuticals. He is responsible for both financial oversight and helps drive company strategy including pre-commercialization work around Marius’s lead asset, Otesso. For the last decade Mr. Shah has held roles focused on public and private investing globally. His experience ranges across sectors and company size. Mr. Shah also has taken on operational role and provided strategic feedback at Board Levels.
James Bernstein, Ph.D
CHIEF SCIENTIFIC OFFICER Dr. Bernstein is a pharmaceutical scientist and consultant with over 29 years of experience in the development of new pharmaceuticals. He began serving as the Chief Scientific Officer of SOV in 2010. In 2007, he founded Live Oak Pharmaceutical Consulting, a full –service CMC consulting practice with a network of 15 experts in drug development. Prior to founding Live Oak, he worked for GSK and heritage companies for 24 years as a scientist, CMC project leader, and manager. He earned a B.S. degree in Chemistry and Physics from Centenary College of Louisiana and a Ph.D. in Physical Chemistry from the University of North Carolina at Chapel Hill.
SVP REGULATORY AFFAIRS Dr. Metz has over 38 years of pharmaceutical industry experience including eighteen years of clinical development research and an additional eighteen years in regulatory affairs with GlaxoSmithKline and its heritage companies. Prior to his retirement from GlaxoSmithKline in November 2010, Dr. Metz was Vice President of U.S. Regulatory Affairs and led the group responsible for providing strategic regulatory support to all early stage pharmaceutical development activities conducted by GSK’s Centers for Excellence in Drug Discovery. In this capacity, he was responsible for overseeing the development, coordination and execution of regulatory strategy across the complete clinical spectrum of GSK discovery research and was involved with regulatory interactions across all FDA Reviewing Divisions.
Roger Rittmaster M.D.
CHIEF MEDICAL OFFICER Roger Rittmaster is board-certified in Internal Medicine and Endocrinology, having trained at the National Institutes of Health. In 1985 he joined the Faculty of Dalhousie University (Halifax, Nova Scotia), eventually becoming Professor of Medicine and Associate Professor of Physiology and Biophysics. His areas of research interest included disorders of androgen and estrogen action, osteoporosis, and thyroid dysfunction. In 1999 he joined GlaxoSmithKline, eventually becoming the Executive Director responsible for the clinical development of dutasteride (Avodart®). During that time he was also an Adjunct Professor at Dalhousie University, continuing his basic science research interests in prostate physiology. In 2011 he retired from GlaxoSmithKline and has since been working as a consultant for several pharmaceutical companies. He currently lives in Camden, Maine.
SENIOR DIRECTOR, OPERATIONAL STRATEGY A 20 year veteran of global life cycle clinical development and project delivery, including data management, safety, regulatory, clinical trial management, with executive program oversight. Most notably, Ms. Fowler was responsible for the global delivery of the REDUCE Trial, which assessed the use of Avodart™ (a 5ARI) in reducing the risk of Prostate Cancer in men considered to be at risk for the disease. The Avodart prostate cancer program included more than 850 study centers in 42 countries and involved more than 8000 men. This work included clinical trial delivery, clinical development planning, Key Opinion Leader relationships, Data Safety Monitoring, scientific advisory committees and publication planning. Ms. Fowler’s therapeutic experience spans a broad range of global development in PH1-IV studies in oncology, immunology, endocrinology, genitourinary, respiratory and metabolic indications, as well as in Quality of Life research.